Vivet Therapeutics Doses First Patient in Cohort 2 in Phase 1/2 GATEWAY Clinical Trial for Treatment of Wilson Disease

Posted on by

Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed in Cohort 1 with lead program VTX-801 PARIS, April 8, 2024 /PRNewswire/ — Vivet Therapeutics (‘Vivet’), a…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.